Reports
Sale
United States Hereditary Angioedema Therapeutics Market Share, Trends, Analysis, Growth, Forecast: By Drug Type: C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others; By Route of Administration: Intravenous, Subcutaneous, Oral; Competitive Landscape; Key Trends and Developments in the Market; 2023-2028
United States Hereditary Angioedema Therapeutics Market Outlook
The United States hereditary angioedema therapeutics market is expected to grow at a CAGR of 8.20% between 2023 and 2028.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Trends in the Market
Hereditary angioedema is a hereditary disorder in which the patient suffers from recurring attacks of severe swelling in body parts including hand, face, feet, and intestinal walls. It is caused by the deficiency or improper functioning of a protein that is C1 inhibitor and can threaten the life of the patient suffering from it.
There are numerous medications and therapies available to treat the condition and help control or prevent the swelling from occurring. Cases of hereditary angioedema in the United States are on the rise, due to genetic mutations and greater accuracy in diagnostics.
- Hereditary angioedema therapies have been progressing with time and now effective medications are available such as Garadacimab. Key players are continuously striving to innovate and develop better products. Patients depending on the therapies are receiving positive results which is ultimately resulting in the growth of the United States hereditary angioedema therapeutics market.
- Unawareness about the disease can lead to misdiagnosis, and delay treatment. Organisations such as the United States Hereditary Angioedema Association spread awareness about the condition, its causes, and treatments available, further supporting the market growth for hereditary angioedema treatment.
- Home based treatments are available for hereditary angioedema which have aided in reducing the seriousness of attacks and improving the quality of life of the patient. A lot of patients are adapting to therapeutics for hereditary angioedema in the United States and are helping n the growth of the market.
Market Analysis
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on drug type, the market can be segmented into C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and others. On the basis of route of administration, the market is divided into intravenous, subcutaneous, and oral.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the United States hereditary angioedema therapeutics market, covering their competitive landscape and latest developments like mergers, acquisitions, investments and expansion plans.
- Takeda Pharmaceutical Company Limited
- BioCryst Pharmaceuticals, Inc.
- Sanofi S.A.
- CSL Behring LLC
- Pharming Group N.V.
- Cipla Inc.
- Ionis Pharmaceuticals Inc.
- Attune Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc
- Others
Market Share by Drug Type
In children aged 12 years and above, hereditary angioedema is treated through drugs such as Kallikrin inhibitors, while in adults, C1 esterase inhibitor and B2 bradykinin receptor antagonist are used. C1 esterase inhibitors, which also act as an anti-inflammatory agent, has been leading the United States hereditary angioedema therapeutics market because it has the potential to treat other diseases too along with hereditary angioedema.
Market Share by Route of Administration
The route of administration of a medicine varies depending upon the condition of the patient and the frequency of medication administration. Intravenous therapy is useful for patients already fitted with IV drips, while subcutaneous therapy can be effective for individuals that need quick administration.
Long term medication is most commonly administered through oral forms to reduce the effect of the disorder. The intravenous process occupies a significant segment of the United States hereditary angioedema therapeutics market as many therapies require urgent administration and fast impact.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
Takeda Pharmaceutical Company Limited founded in 1781 has its headquarter in Tokyo, Japan. It is a global pharmaceutical company that carries out research and innovates in medicine for better health of patients worldwide.
BioCryst Pharmaceuticals, Inc. was established in 1986 with headquarters in North Carolina, United States. It is an American biotech company that deals with medicines, particularly oral drugs, that are prescribed for rare diseases.
Sanofi S.A. founded in 2004 has its headquarter located in Paris, France. It is a healthcare company that manufactures vaccines and medicines for rare blood disorders, cardiovascular diseases, diabetes, and various other serious diseases.
Other market players include CSL Behring LLC, Pharming Group N.V., Cipla Inc., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Inc., and Adverum Biotechnologies, Inc among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
7 Industry Opportunities and Challenges
8 United States Hereditary Angioedema Therapeutics Market Analysis
8.1 Key Industry Highlight
8.2 United States Hereditary Angioedema Therapeutics Historical Market (2018-2022)
8.3 United States Hereditary Angioedema Therapeutics Market Forecast (2023-2028)
8.4 United States Hereditary Angioedema Therapeutics Market by Drug Type
8.4.1 C1-Esterase Inhibitor
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Bradykinin B2 Receptor Antagonist
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 Kallikrein Inhibitor
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.4.4 Others
8.5 United States Hereditary Angioedema Therapeutics Market by Route of Administration
8.5.1 Intravenous
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Subcutaneous
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Oral
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2022)
8.5.3.3 Forecast Trend (2023-2028)
9 Market Dynamics
9.1 SWOT Analysis
9.1.1 Strengths
9.1.2 Weaknesses
9.1.3 Opportunities
9.1.4 Threats
9.2 Porter’s Five Forces Analysis
9.2.1 Supplier’s Power
9.2.2 Buyer’s Power
9.2.3 Threat of New Entrants
9.2.4 Degree of Rivalry
9.2.5 Threat of Substitutes
10 Competitive Landscape
10.1 Market Structure
10.2 Company Profiles
10.2.1 Takeda Pharmaceutical Company Limited
10.2.1.1 Company Overview
10.2.1.2 Product Portfolio
10.2.1.3 Demographic Reach and Achievements
10.2.1.4 Certifications
10.2.2 BioCryst Pharmaceuticals, Inc.
10.2.2.1 Company Overview
10.2.2.2 Product Portfolio
10.2.2.3 Demographic Reach and Achievements
10.2.2.4 Certifications
10.2.3 Sanofi S.A.
10.2.3.1 Company Overview
10.2.3.2 Product Portfolio
10.2.3.3 Demographic Reach and Achievements
10.2.3.4 Certifications
10.2.4 CSL Behring LLC.
10.2.4.1 Company Overview
10.2.4.2 Product Portfolio
10.2.4.3 Demographic Reach and Achievements
10.2.4.4 Certifications
10.2.5 Pharming Group N.V.
10.2.5.1 Company Overview
10.2.5.2 Product Portfolio
10.2.5.3 Demographic Reach and Achievements
10.2.5.4 Certifications
10.2.6 Cipla Inc.
10.2.6.1 Company Overview
10.2.6.2 Product Portfolio
10.2.6.3 Demographic Reach and Achievements
10.2.6.4 Certifications
10.2.7 Ionis Pharmaceuticals Inc.
10.2.7.1 Company Overview
10.2.7.2 Product Portfolio
10.2.7.3 Demographic Reach and Achievements
10.2.7.4 Certifications
10.2.8 Attune Pharmaceuticals, Inc.
10.2.8.1 Company Overview
10.2.8.2 Product Portfolio
10.2.8.3 Demographic Reach and Achievements
10.2.8.4 Certifications
10.2.9 Adverum Biotechnologies, Inc
10.2.9.1 Company Overview
10.2.9.2 Product Portfolio
10.2.9.3 Demographic Reach and Achievements
10.2.9.4 Certifications
10.2.10 Others
11 Key Trends and Developments in the Market
List of Figures and Tables
1. United States Hereditary Angioedema Therapeutics Market: Key Industry Highlights, 2018 and 2028
2. United States Hereditary Angioedema Therapeutics Historical Market: Breakup by Drug Type (USD Million), 2018-2022
3. United States Hereditary Angioedema Therapeutics Market Forecast: Breakup by Drug Type (USD Million), 2023-2028
4. United States Hereditary Angioedema Therapeutics Historical Market: Breakup by Route of Administration (USD Million), 2018-2022
5. United States Hereditary Angioedema Therapeutics Market Forecast: Breakup by Route of Administration (USD Million), 2023-2028
6. United States Hereditary Angioedema Therapeutics Market Structure
Key Questions Answered in the Report
The market is expected to grow at a CAGR of 8.20% between 2023 and 2028.
Improving awareness levels, rising cases of the condition, and increasing genetic mutations are the major market drivers.
The key trends of the market are development and innovations, awareness programmes, and home-based treatments.
Key market players include Takeda Pharmaceutical Company Limited, BioCryst Pharmaceuticals, Inc., Sanofi S.A., CSL Behring LLC, Pharming Group N.V., Cipla Inc., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Inc., and Adverum Biotechnologies, Inc, among others.
Hereditary angioedema is a condition in which the patient suffers from recurring attacks of severe swelling in body parts including hands, face, feet, and intestinal walls.
The United States hereditary angioedema therapeutics market is segmented based on drug type and route of administration.
Hereditary angioedema is caused by the deficiency or improper functioning of a protein that is a C1 inhibitor.
Some of the drug types are C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 2199
$1799
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$3199$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$4199$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$5199$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER